Al-Dawaa Medical Services Company (4163) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Al-Dawaa Medical Services Company stock SAR 79.49, price SAR 38.46, upside +106.7%, quality 61 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
56‑month range 34.32 SAR – 108.20 SAR · fair‑value band 59.62 SAR – 99.37 SAR · the 38.46 SAR price screens below the 79.49 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Al-Dawaa Medical Services in your weekly email
Every Wednesday you see whether Al-Dawaa Medical Services is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Al-Dawaa Medical Services Company, together with its subsidiaries, primarily operates as a pharmaceutical retail company in the Kingdom of Saudi Arabia and Kingdom of Bahrain.
Show moreShow less
The company offers medicines, perfumes, cosmetics, beauty tools, and other pharmaceutical products; and transportation and logistics services.
It is also involved in online wholesale of pharmaceutical products, pharmaceutical agents, wholesale of pharmaceutical goods, related pharmacy activities, pharmaceutical warehousing activities, retail of medical equipment and other equipment; online retailing, land transport of goods, providing delivery services via electronic platforms; managing and renting self-storage stores and manufacturing of single-use medical products and disposables; manufacturing of single-use medical products, consumables, medical examination tables, surgical furniture, beds with mechanical motion additives, medical thermometers, and respirators and medical anesthesia; marketing activities; and marketing licenses for pharmaceutical products, consumer goods and food products.
Al-Dawaa Medical Services Company was founded in 1993 and is based in Al Khobar, the Kingdom of Saudi Arabia.
Stock analysis
Al-Dawaa Medical Services Company (4163) currently trades at 38.46 SAR, while our model-based Fair Value estimate is 79.49 SAR, implying the stock looks roughly 52% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 90.18 SAR per share, and 20 of the 26 models we run sit above the 38.46 SAR price.
Bear case: the Asset-Based group reads lowest at 11.29 SAR, and 6 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 59.62 SAR (bear) to 99.37 SAR (bull), the price of 38.46 SAR sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Al-Dawaa Medical Services Company reported revenue of 6.7B SAR in FY2025 versus 5.0B SAR in FY2021, a compound +7.6%/yr. Reported net income was 322M SAR in FY2025, compounding +7.7%/yr from FY2021.
Key figures
Market cap 3.3B SAR (≈ $871M) Small · P/E ratio 18.0 · P/S ratio 0.49 · EPS (TTM) 2.14 SAR · Dividend yield 3.3% · Net margin 2.8% · Return on equity 12.7% · Return on assets (EBIT) 8.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 44 out of 100 (low confidence).
What moves the price
The share trades about 36% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 19% fair-value upside, at 107%, 4163 screens cheaper than that median.
Fair Value models
Bear59.62 SARFair Value 79.49 SARBull99.37 SAR
Price 38.46 SAR · Upside +106.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.7546 SAR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.72/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+4.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.3%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.0%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+8.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+5.5%
Dividend (yield on the price)3.3%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 7%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−4.3%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (Saudi Arabia: IMF forecast 2.1% a year to 2030, 1.7% from 2016 to 2025) that is about −6.3% a year for the price and +1.0% for the forecasts.
Compare Al-Dawaa Medical Services Company with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 50 stocks
Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score61 · Top 25%
Fair Value upside+108.2% · Top 25%
Profitability
Return on equity (12 months)12.7% · Top 25%
Return on assets6.2% · Top 25%
Net margin (12 months)2.8% · Above median
Operating margin (12 months)4.4% · Above median
Growth and dividend
Revenue growth (quarter YoY)−2.9% · Bottom 25%
Dividend yield (12 months)3.3% · Above median
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
P/E (12 months)18.0× · Cheaper than median
P/B2.24× · Pricier than median
P/S (12 months)0.49× · Cheaper than median
Price / free cash flow (fiscal year)6.4× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Al-Dawaa Medical Services Company Fair Value". https://www.fairvalue-calculator.com/stock/4163
Frequently asked questions
Is Al-Dawaa Medical Services Company (4163) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 79.49 SAR versus a price of 38.46 SAR, about +107% upside (undervalued).
What is the fair value of 4163?
Our model-based fair value for Al-Dawaa Medical Services Company is 79.49 SAR (as of Nov 9, 2026), built from audited fundamentals. The current price: 38.46 SAR.
What is the quality score of 4163?
Al-Dawaa Medical Services Company has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Al-Dawaa Medical Services Company (4163)?
Our model-based price target is the fair value of 79.49 SAR (as of Nov 9, 2026) from 26 valuation models. Cautious scenario 59.62 SAR, optimistic scenario 99.37 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Al-Dawaa Medical Services Company stock forecast for 2026?
Our models put fair value at 79.49 SAR, about +107% upside versus a price of 38.46 SAR (undervalued). Cautious scenario 59.62 SAR, optimistic scenario 99.37 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Al-Dawaa Medical Services Company (4163)?
Al-Dawaa Medical Services Company reported trailing-twelve-month revenue of about 6.6B SAR (latest available figure, as of Nov 9, 2026).
Does Al-Dawaa Medical Services Company pay a dividend?
Al-Dawaa Medical Services Company currently shows a dividend yield of 3.28% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Al-Dawaa Medical Services Company (4163) and when is the ex-dividend date?
Al-Dawaa Medical Services Company pays a dividend of 1.26 SAR per share a year, a dividend yield of 3.3%. The last ex-dividend date was Jul 7, 2026. A dividend has been paid every year since at least 2022. The payout ratio is 58.9% of earnings. Free cash flow covers the dividend 4.75 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Al-Dawaa Medical Services Company (4163)?
For today's price to be fair in a discounted-cash-flow model, Al-Dawaa Medical Services Company would have to grow free cash flow by -4.3 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.3 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 4163 use?
Our models discount Al-Dawaa Medical Services Company at 11.8 %: a base by market capitalisation (small), country premium for Saudi Arabia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Al-Dawaa Medical Services Company that is -4.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Al-Dawaa Medical Services Company (4163) delivered so far?
Over the past 5 years revenue at Al-Dawaa Medical Services Company grew +6.3 % a year. The price currently implies free-cash-flow growth of -4.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Al-Dawaa Medical Services Company (4163) growing?
The median revenue growth in the sector is +3.6 % a year. That is the yardstick for the growth priced into Al-Dawaa Medical Services Company (-4.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Al-Dawaa Medical Services Company (4163)?
The free-cash-flow yield on the price is 15.55 %: that much free cash flow Al-Dawaa Medical Services Company produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Al-Dawaa Medical Services Company (4163)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Al-Dawaa Medical Services Company it is 79.49 SAR per share (as of Nov 9, 2026), against a price of 38.46 SAR. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Al-Dawaa Medical Services Company stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 4163 trades below its calculated fair value: price 38.46 SAR, fair value 79.49 SAR, a gap of about +107% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4163?
No. The price is what the market pays today (38.46 SAR); the fair value is what the company's own numbers justify (79.49 SAR). For Al-Dawaa Medical Services Company the two are 41.03 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Al-Dawaa Medical Services Company worth?
The market values Al-Dawaa Medical Services Company at about 3.3B SAR (market capitalisation, as of Nov 9, 2026). Per share that is 38.46 SAR; our models calculate a fair value of 79.49 SAR per share.
What do the bullish and bearish scenarios say about 4163?
Our models span a range for Al-Dawaa Medical Services Company: cautious scenario 59.62 SAR, base 79.49 SAR, optimistic 99.37 SAR per share (as of Nov 9, 2026, price 38.46 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4163?
Al-Dawaa Medical Services Company trades at a price-to-earnings ratio of 18.0 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 79.49 SAR is built from several models across several years. Other multiples: P/B 2.2, P/S 0.5, EV/EBITDA 6.3.
How solid is the balance sheet of Al-Dawaa Medical Services Company (4163)?
Balance-sheet figures for Al-Dawaa Medical Services Company (as of Nov 9, 2026): return on equity 12.7%. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is 4163 from its 52-week high?
Al-Dawaa Medical Services Company trades at 38.46 SAR, about 36% below its 52-week high of 60.43 SAR and 12% above the low of 34.32 SAR (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 79.49 SAR is for.
Which stocks are comparable to Al-Dawaa Medical Services Company?
From the same area (Healthcare) we also value JD Health International Inc, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Al-Dawaa Medical Services Company stock attractive at the current price?
The data as of Nov 9, 2026: price 38.46 SAR, calculated fair value 79.49 SAR (+107%), Quality Score 61/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4163 calculated?
We run Al-Dawaa Medical Services Company through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 79.49 SAR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Al-Dawaa Medical Services Company currently trades 52% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Al-Dawaa Medical Services Company (4163)?
The closing price on Nov 9, 2026 was 38.46 SAR. Our model-based fair value is 79.49 SAR, about +107% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Al-Dawaa Medical Services Company right now?
The price is below even our cautious bear case (59.62 SAR). The market is more pessimistic than our downside scenario. Solid quality (61/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Al-Dawaa Medical Services Company
How large is the market capitalisation of Al-Dawaa Medical Services Company (4163)?
The market capitalisation of Al-Dawaa Medical Services Company is 3.3B SAR (≈ $871M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Al-Dawaa Medical Services Company (4163)?
The price-to-sales ratio of Al-Dawaa Medical Services Company is 0.49 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Al-Dawaa Medical Services Company (4163)?
Earnings per share at Al-Dawaa Medical Services Company are 2.14 SAR (price ÷ EPS = P/E 18.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Al-Dawaa Medical Services Company (4163)?
The dividend yield of Al-Dawaa Medical Services Company is 3.3% (payout 58.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Al-Dawaa Medical Services Company (4163)?
The net margin of Al-Dawaa Medical Services Company is 2.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Al-Dawaa Medical Services Company (4163)?
The return on equity (ROE) of Al-Dawaa Medical Services Company is 12.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Al-Dawaa Medical Services Company (4163)?
On an EBIT basis the return on assets of Al-Dawaa Medical Services Company is 8.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Al-Dawaa Medical Services Company (4163)?
The operating margin of Al-Dawaa Medical Services Company is 4.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Al-Dawaa Medical Services Company (4163)?
Revenue at Al-Dawaa Medical Services Company is growing −2.9% versus a year earlier (3y avg +7.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Al-Dawaa Medical Services Company (4163)?
Earnings per share at Al-Dawaa Medical Services Company are growing −65.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Al-Dawaa Medical Services Company (4163) carry?
The net debt of Al-Dawaa Medical Services Company is 509M SAR (fiscal year 2025, ≈ 1.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Al-Dawaa Medical Services Company in the live analysis
One click puts Al-Dawaa Medical Services Company on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 9, 2026